-
02:35:55 AM

SESN Stock News

01/26/23 8:00 AM
Nasdaq : SESN
acquisition
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
Sesen Bio, Inc. today issued the following statement reiterating the Company’ s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates:. In contrast, we believe the Investor Group continues to be opportunistic and single-minded,...
RHEA-AI
neutral
01/25/23 8:00 AM
Nasdaq : SESN
acquisition
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
Bradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today issued the following open letter to the Boards of Directors of Sesen Bio and Carisma Therapeutics Inc.:. Members of the Sesen Bio and Carisma Boards,. The cash dividend being paid to Sesen Bio stockholders is, in our view, insufficient. The proposed...
RHEA-AI
neutral
01/19/23 4:28 PM
Nasdaq : SESN
acquisition
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
Sesen Bio, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’ s pending merger with Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
RHEA-AI
neutral
01/05/23 8:00 AM
Nasdaq : SESN
managementacquisition
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
Bradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today issued the following open letter to the Company’ s Board of Directors regarding the proposed merger with Carisma Therapeutics Inc.:. The Investor Group remains adamantly opposed to Sesen Bio’ s proposed merger with Carisma. Last week’ s...
RHEA-AI
neutral
01/03/23 8:00 AM
Nasdaq : SESN
acquisition
Investor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with Carisma
Bradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today reiterated their intent to vote AGAINST the Company’ s proposed merger with Carisma Therapeutics Inc. through the following statement:. “After reviewing the amended merger terms disclosed last week, the Investor Group remains firmly opposed...
RHEA-AI
neutral
12/29/22 4:33 PM
Nasdaq : SESN
dividendsacquisition
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
Sesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced an amendment to their previously announced merger agreement dated September 20, 2022. Under the terms of the amended merger agreement,...
RHEA-AI
positive